Ann: Race Leadership Changes, page-141

Very obvious Tillet and Culity didn’t see eye to eye, we should have booted JC out when we had the chance but seems no one wanted to support this last year.

Its a-shame for Daniel but don’t think it detracts from legacy and won’t detract from his investment, or ultimately patients.

if anything, this decision will get Zantrene into patients faster.

Whilst we likely have a board that now wants to see a commercial transaction happen faster & potential at a lower value than if tillet had his way by proving more of it out, The benefit I see is tillet has now more power to influence through his connections, voting power being the largest shareholder, and can possibly guide without letting the science get in the way.

Now it becomes an investment for him as opposed to being in control of the science.

Let’s see if they let some IP go in the near future and get us up to a more realistic market cap before the sharks take a bite.